Mirae Asset Global Investments Co. Ltd. Acquires 537,976 Shares of AbbVie Inc. $ABBV

Key Points

• Mirae Asset Global Investments acquired 537,976 AbbVie shares in the third quarter, valued at approximately $140.7 million. Institutional investors collectively own 70.23% of the company.
• AbbVie’s latest quarterly results exceeded expectations, with earnings of $3.82 per share and revenue of $17.4 billion, up 10.3% year over year. The company also declared a quarterly dividend of $1.73 per share, equivalent to a 2.3% annual yield.
• ABBV was trading near its 52-week high at $294.80, while analysts maintained a consensus “Moderate Buy” rating with an average price target of $279.86, highlighting potential valuation concerns despite strong growth.

Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of AbbVie Inc. (NYSE:ABBV - Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 537,976 shares of the company's stock, valued at approximately $140,729,000.

Other hedge funds also recently made changes to their positions in the company. Lifelong Wealth Advisors Inc. boosted its stake in AbbVie by 2.1% in the third quarter. Lifelong Wealth Advisors Inc. now owns 1,755 shares of the company's stock valued at $459,000 after acquiring an additional 36 shares during the last quarter. IMG Wealth Management Inc. increased its stake in shares of AbbVie by 22.8% during the 3rd quarter. IMG Wealth Management Inc. now owns 194 shares of the company's stock worth $51,000 after purchasing an additional 36 shares during the last quarter. Foundry Financial Group Inc. increased its stake in shares of AbbVie by 4.6% during the 3rd quarter. Foundry Financial Group Inc. now owns 839 shares of the company's stock worth $219,000 after purchasing an additional 37 shares during the last quarter. James T. Borello RIA increased its stake in shares of AbbVie by 3.5% during the 3rd quarter. James T. Borello RIA now owns 1,192 shares of the company's stock worth $312,000 after purchasing an additional 40 shares during the last quarter. Finally, ACT Advisors LLC. raised its holdings in shares of AbbVie by 2.5% in the 2nd quarter. ACT Advisors LLC. now owns 1,688 shares of the company's stock worth $425,000 after purchasing an additional 41 shares during the period. 70.23% of the stock is currently owned by institutional investors.

AbbVie Trading Up 1.4%

ABBV stock opened at $294.80 on Friday. The firm has a 50 day moving average of $269.35 and a 200-day moving average of $237.23. AbbVie Inc. has a 12 month low of $190.75 and a 12 month high of $298.74. The firm has a market capitalization of $520.85 billion, a P/E ratio of 50.74, a price-to-earnings-growth ratio of 1.35 and a beta of 0.24.

AbbVie (NYSE:ABBV - Get Free Report) last released its quarterly earnings results on Friday, October 30th. The company reported $3.82 EPS for the quarter, beating analysts' consensus estimates of $3.73 by $0.09. The firm had revenue of $17.40 billion during the quarter, compared to analyst estimates of $17.32 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business's revenue for the quarter was up 10.3% on a year-over-year basis. During the same period in the previous year, the business earned $1.86 EPS. Sell-side analysts predict that AbbVie Inc. will post 13.92 EPS for the current year.

AbbVie Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $6.92 annualized dividend and a yield of 2.3%. AbbVie's dividend payout ratio (DPR) is currently 195.48%.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q3 results beat expectations. Adjusted earnings per share were $3.82 versus the $3.73 analyst consensus, while revenue rose 10.3% year over year to $17.404 billion, ahead of the $17.32 billion estimate. Adjusted EPS more than doubled from the prior-year quarter. AbbVie Reports Third-Quarter 2026 Financial Results
• Positive Sentiment: Immunology and neuroscience provided strong momentum. Skyrizi generated $5.776 billion in revenue and Rinvoq produced $2.706 billion, helping immunology revenue increase 16.3%. Neuroscience revenue climbed 19.4%, led by Vraylar, therapeutic Botox, Ubrelvy and Qulipta. AbbVie Lifts 2026 Outlook as Immunology, Neuroscience Quarterly Sales Beat Views
• Positive Sentiment: Management raised guidance and its dividend. AbbVie increased its 2026 adjusted EPS outlook to $13.95–$13.99 from $13.76–$13.96, despite including $0.69 per share of year-to-date acquired in-process research and development and milestone expenses. The company also announced a 5.2% dividend increase beginning with the February 2027 payment. AbbVie Raises FY26 Adjusted EPS Outlook and Boosts Dividend
• Positive Sentiment: Pipeline expansion supports longer-term confidence. AbbVie completed its acquisition of Apogee Therapeutics, strengthening its immunology pipeline, while Qulipta also outperformed topiramate in a Phase 3 migraine-prevention study. AbbVie QULIPTA Phase 3 Migraine Prevention Trial
• Negative Sentiment: Investors remain focused on valuation and concentration risks. Humira revenue fell 31.2% to $683 million, while aesthetics revenue declined 1.4%. After a substantial multiyear rally and trading near its 52-week high, analysts question whether additional valuation expansion is justified and how effectively AbbVie can sustain growth beyond Skyrizi and Rinvoq. Skyrizi and Rinvoq Dominate AbbVie Q3

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on ABBV. Oppenheimer increased their price objective on AbbVie from $244.00 to $258.00 and gave the company a "neutral" rating in a report on Monday, August 3rd. Canaccord Genuity Group boosted their target price on AbbVie from $282.00 to $290.00 and gave the company a "buy" rating in a research note on Monday, August 3rd. Cantor Fitzgerald upped their price target on AbbVie from $285.00 to $290.00 and gave the company an "overweight" rating in a research report on Thursday, October 8th. Erste Group Bank upgraded shares of AbbVie from a "hold" rating to a "buy" rating in a research report on Wednesday, August 5th. Finally, Wells Fargo & Company lifted their target price on shares of AbbVie from $295.00 to $300.00 and gave the stock an "overweight" rating in a research note on Monday, August 17th. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $279.86.

Insider Buying and Selling

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the firm's stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the sale, the executive vice president owned 74,430 shares of the company's stock, valued at $18,607,500. This trade represents a 30.53% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.06% of the stock is currently owned by insiders.

About AbbVie

AbbVie Inc NYSE: ABBV is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company's key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.